A patient asks for Wegovy. Their plan doesn't cover it, or the prior authorization comes back denied. The next question may be some version of: is there another way to get a GLP-1 medication, and is it the same thing? The answer runs through three separate FDA frameworks — approval, compounding, and the agency's own safety warnings about this specific drug class.
What FDA approval means
FDA approval means the agency has reviewed a sponsor's research data on a drug and made a decision on whether to approve it. Getting there runs through laboratory and animal testing, then a series of studies in people to check safety and effectiveness, then an FDA review of all the submitted evidence before a decision is made. FDA doesn't stop watching once a drug is approved — it continues to monitor safety data, review advertising claims, and oversee product quality after the drug is on the market. Wegovy and Zepbound went through that full process and carry FDA approval for chronic weight management.
What compounding is — and isn't — under FDA rules
Compounding is a different track entirely. A pharmacist or physician prepares a drug outside FDA's standard manufacturing process, typically to meet a need an FDA-approved drug doesn't meet — for example, a patient with an allergy to an inactive ingredient, or one who can't take the approved dosage form. Compounded drugs are not FDA-approved: FDA does not verify their safety, effectiveness, or quality before they reach a patient. Outsourcing facilities, one type of compounder, are subject to current good manufacturing practice (CGMP) requirements. That's a structural fact about the category, not a judgment on any single pharmacy's work. It's also why no compounded product can accurately be called "FDA-approved," including compounded semaglutide or tirzepatide.
What FDA has said about compounded and counterfeit GLP-1s
FDA has issued specific warnings about this category, separate from its general compounding guidance. The agency says patients and prescribers turning to unapproved versions of GLP-1 drugs for weight loss take on risk those versions haven't been reviewed for. Two separate problems sit inside that warning. One is quality and handling: FDA has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, including patients and clinicians miscalculating amounts. The other is fraudulent labeling: FDA has found products using a real, licensed pharmacy's name without that pharmacy having made the product. FDA's recommendation is to use an FDA-approved GLP-1 where a patient's medical needs allow it, get any prescription from a licensed prescriber filled at a state-licensed pharmacy, and report suspected problems through its MedWatch program.
What a practice should tell patients
None of this is a patient choosing a product off a menu — a provider reviews a patient's history and decides what's appropriate. But patients asking about compounded GLP-1 are entitled to a plain explanation of where it sits regulatorily, separate from whether it's clinically right for them:
That FDA hasn't verified the specific product they'd receive. That absence of pre-market verification is true of every compounded drug, not just GLP-1s.
That counterfeits exist in this category specifically. FDA has documented fraudulent products using fake or borrowed pharmacy names.
That questions about how a specific product was prepared or where it came from are reasonable to ask. A practice that can answer those questions — and one that can't — tells a patient something about how seriously that regulatory gap is being managed.
A program offering either path, or both, is operating inside these same FDA frameworks whether it says so out loud or not.
Some programs include compounded or off-label therapies. Treatment appropriateness is determined by a licensed provider after individual evaluation. Build.MD does not provide medical care directly; all clinical services are provided by Access Plus Medical or its affiliated providers. Compounded medications are not FDA-approved and are prepared by licensed pharmacies for individual patients.
Editorial standards: how these posts are researched, sourced, and reviewed.
← All posts